{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Observational patient registry"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2145309"],"location":["China"],"study_start_month":["6"],"keyword":["Adverse events","Overall survival","Tumor resection rate","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer","description":"This observational, multicenter, prospective study will evaluate the use of bevacizumab in real clinical practice in chinese patients with metastatic colorectal cancer.","dates":{"creation":"2012-06-15"},"accession":"2145309","cross_references":{"ClinicalTrials___gov":["NCT01860144"]}}